✨ Free AI Report
Aclaris Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Aclaris Therapeutics, Inc.
Company Research

Aclaris Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Aclaris Therapeutics, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Clinical-stage biotech positioned to derisk key immuno-inflammatory programs through 2026 with multiple data readouts expected. Aclaris demonstrates solid execution with multiple clinical catalysts in 2026 and positive Phase 1a data derisking early programs. However, the company is pre-revenue clinical stage with significant development risk ahead, though cash runway extends.

What is Aclaris Therapeutics, Inc.'s industry? Aclaris Therapeutics, Inc. (aclaristx.com) operates in Biopharmaceuticals - Immuno-inflammatory Therapeutics. AskCyborg classifies Aclaris Therapeutics, Inc. under Biopharmaceuticals - Immuno-inflammatory Therapeutics in its company registry.

Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases. The company is advancing a multi-program pipeline targeting significa...

6/ 10Solid

Cyborg Score thesis

Clinical-stage biotech positioned to derisk key immuno-inflammatory programs through 2026 with multiple data readouts...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Immuno-inflammatory Therapeutics
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Aclaris Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Aclaris Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Aclaris Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Aclaris Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Aclaris Therapeutics, Inc. Overview

Pro stress-test →

Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases. The company is advancing a multi-program pipeline targeting significant unmet needs in dermatology and immunology with both small-molecule and biologic candidates.

Strategic Profile

Pro stress-test →

The company achieved strong business execution in 2025 with continued momentum across programs, and 2026 has started with derisking events for two key programs (ITK and ATI-052). Aclaris maintains a strong cash position with several meaningful catalysts expected across its biologics and ITK pipeline this year.

Competitive Landscape

Pro stress-test →

Aclaris competes in the immuno-inflammatory therapeutics space against companies developing JAK inhibitors, monoclonal antibodies, and ITK inhibitors. Key competitive programs include ritlecitinib (Pfizer, alopecia areata) and various TSLP-targeting biologics. Aclaris differentiates through its bispecific ATI-052 platform combining dual pathway inhibition and its proprietary ITK-selective inhibitor technology.

Industry Context

Aclaris Therapeutics, Inc. operates in Biopharmaceuticals - Immuno-inflammatory Therapeutics.

Key facts

Founded: 2016 · Headquarters: Wayne, PA · Revenue: $1.30M · Market cap: $339.14M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Aclaris Therapeutics, Inc..

  • ATI-052 Phase 1a trial demonstrated strong safety and tolerability profiles with robust target engagement validating compound potency at low doses.
  • Lead ITK inhibitor ATI-9494 has shown potent Th1/Th2 blockade and prolonged half-life, with IND application expected in H2 2026.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026Positive Phase 1a interim results for ATI-052 bispecific antibody showing strong safety and target engagement
  • Feb 2026Initiated two Phase 1b proof-of-concept trials for ATI-052 in atopic dermatitis and asthma
  • +2 moreTrack every material event for Aclaris Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Aclaris Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

RitlecitinibJAK inhibitor for alopecia areata→DupilumabAnti-IL-4R monoclonal antibody for atopic dermatitis and asthma→TezepelumabAnti-TSLP monoclonal antibody for asthma→

Compare Aclaris Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Aclaris Therapeutics, Inc. operates in Biopharmaceuticals - Immuno-inflammatory Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Immuno-inflammatory Therapeutics research →
NEW · MCP server

Ask your AI assistant about Aclaris Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Aclaris Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Aclaris Therapeutics, Inc. do this quarter?”
“Is Aclaris Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Aclaris Therapeutics, Inc. do?+
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases. The company is advancing a multi-program pipeline targeting significa...
What is Aclaris Therapeutics, Inc.'s Cyborg Score?+
Aclaris Therapeutics, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Aclaris Therapeutics, Inc.'s main competitors?+
Named competitors include Ritlecitinib, Dupilumab, Tezepelumab. The full competitive landscape is in the AskCyborg report.
How can I get the full Aclaris Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Aclaris Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Aclaris Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.